Ovarian cancer is a highly chemotherapy-sensitive malignancy. With current treatment, most women presenting with advanced disease will achieve an objective response and experience major and sustained improvement of cancer-related symptoms. Unfortunately, the majority of patients will ultimately recur, such that second-line treatment options will need to be considered. Further complicating the decision-making process in choosing an 'optimal' second-line regimen is a serious paucity of randomized trials in this clinical setting.
No takes yet. Share an insight, caveat, or question.
Maurie Markman (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: